Gritstone oncology, inc. (GRTS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Dec'17
Assets
Current assets:
Cash and cash equivalents

54,860

57,408

116,942

107,728

34,572

52,183

65,936

39,007

Marketable securities

54,020

70,368

32,523

73,511

97,590

100,927

11,486

46,946

Prepaid expenses and other current assets

3,466

3,497

5,318

3,458

2,838

4,526

6,728

2,526

Total current assets

112,346

131,273

154,783

184,697

135,000

157,636

84,150

88,479

Property and equipment, net

25,847

26,911

24,376

18,966

15,652

29,494

27,012

27,211

Operating lease right-of-use assets

22,130

23,427

24,780

21,309

22,018

0

-

-

Deposits and other long-term assets

2,695

2,778

2,709

2,700

2,817

2,428

2,039

1,610

Long-term marketable securities

-

-

2,003

508

-

-

-

-

Total assets

163,018

184,389

208,651

228,180

175,487

189,558

113,201

117,300

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

5,008

4,621

6,737

5,253

3,622

4,825

3,874

3,935

Accrued compensation

2,775

4,598

3,725

2,621

1,694

3,951

2,400

2,227

Accrued liabilities

414

1,041

2,147

1,803

803

740

2,238

1,490

Accrued research and development expenses

2,311

1,779

3,241

-

-

252

-

-

Lease liabilities, current portion

3,421

2,505

1,642

2,890

2,574

0

-

-

Deferred revenue, current portion

4,511

4,956

5,401

5,498

5,419

5,340

-

-

Deferred revenue, current portion

-

-

-

-

-

-

5,210

-

Total current liabilities

18,440

19,500

22,893

18,065

14,112

15,108

13,722

7,652

Deferred rent, net of current portion

-

-

-

-

-

1,353

1,567

1,749

Other non-current liabilities

-

-

-

-

2

12

25

96

Lease financing obligation, net of current portion

-

-

-

-

-

10,490

-

-

Lease liabilities, net of current portion

20,101

20,985

19,432

16,919

17,104

0

-

-

Lease financing obligation, net of current portion

-

-

-

-

-

-

10,502

10,521

Deferred revenue, net of current portion

9,088

9,560

9,931

10,818

12,047

13,473

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

14,694

-

Total liabilities

47,629

50,045

52,256

45,802

43,265

40,436

40,510

20,018

Commitments and contingencies (Notes 6 and 8)

-

-

-

-

-

-

0

-

Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding

0

0

-

-

-

0

177,872

156,937

Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2020 and December 31, 2019; 36,985,739 and 36,332,956 shares issued and outstanding at March 31, 2020 and December 31, 2019

17

17

17

17

16

16

2

1

Additional paid-in capital

362,586

355,291

349,631

348,021

276,703

275,593

3,885

2,045

Accumulated other comprehensive (loss) gain

-20

24

31

76

67

-85

-5

-74

Accumulated deficit

-247,194

-220,988

-193,284

-165,736

-144,564

-126,402

-109,063

-61,627

Total stockholders’ equity

115,389

134,344

156,395

182,378

132,222

149,122

72,691

97,282

Total liabilities and stockholders’ equity

163,018

184,389

208,651

228,180

175,487

189,558

113,201

117,300